Additional Metabolic Peptides

Modern metabolic medicine extends far beyond GLP-1 receptor agonists. While medications such as semaglutide, tirzepatide, and retatrutide currently possess the strongest body of clinical evidence for obesity treatment, researchers continue investigating numerous peptide therapies that target metabolism through entirely different biological mechanisms.

Rather than primarily suppressing appetite, many of these emerging peptides are designed to influence body composition, mitochondrial function, growth hormone signaling, insulin sensitivity, lipid metabolism, or visceral fat reduction. Some have decades of clinical experience in specific medical conditions, while others remain investigational with promising—but still limited—human data.

As interest in peptide medicine has expanded, so has the number of compounds marketed for weight loss and body composition improvement. It is important to recognize that these therapies differ substantially in the quality of scientific evidence supporting their use. Some have been evaluated in large randomized clinical trials, while others are supported only by preliminary human studies or preclinical laboratory research.

Understanding these differences helps patients and clinicians make informed, evidence-based decisions.

Beyond GLP-1 Therapy

  • MOTS-C

    MOTS-c

    MOTS-c is a naturally occurring mitochondrial-derived peptide that represents an entirely different class of metabolic signaling molecules.

    Unlike gut hormones, MOTS-c originates within the mitochondria—the cellular structures responsible for energy production.

    Research suggests MOTS-c may influence:

    • Cellular energy utilization

    • Glucose metabolism

    • Insulin sensitivity

    • Exercise adaptation

    • Fat oxidation

    • Mitochondrial efficiency

    Animal studies have demonstrated improvements in metabolic flexibility and exercise performance, while early human investigations suggest potential metabolic benefits. However, human clinical evidence remains relatively limited, and many questions regarding optimal dosing, long-term safety, and clinical effectiveness remain unanswered.

    Because of its unique mechanism, MOTS-c is often discussed alongside lifestyle interventions such as resistance training and aerobic exercise rather than as a replacement for them.

    Learn More

  • AOD-9604

    AOD-9604 is a modified fragment of human growth hormone consisting of amino acids 176–191.

    Unlike full-length growth hormone, AOD-9604 was specifically engineered to retain portions of growth hormone's lipolytic signaling while minimizing many of its anabolic effects.

    Laboratory studies have suggested potential effects on:

    • Fat metabolism

    • Lipolysis

    • Fat oxidation

    • Adipocyte function

    Despite encouraging early research, clinical trials evaluating AOD-9604 for obesity have produced mixed results. To date, the overall evidence has not demonstrated weight-loss outcomes comparable to modern incretin therapies, and the peptide is not approved by the U.S. Food and Drug Administration for obesity treatment.

    Interest in AOD-9604 continues within research settings, but considerably more evidence is needed before its role can be clearly defined.

    Learn More

  • Tesamorelin

    Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce pulsatile growth hormone release.

    Unlike administering growth hormone directly, tesamorelin works upstream within the body's normal endocrine axis, producing more physiologic increases in endogenous growth hormone and insulin-like growth factor-1 (IGF-1).

    Tesamorelin is FDA-approved for the treatment of excess visceral adipose tissue in adults with HIV-associated lipodystrophy, where numerous clinical trials have demonstrated meaningful reductions in abdominal visceral fat while largely preserving lean body mass.

    Outside this indication, clinicians have become increasingly interested in its potential role in body composition optimization because visceral fat is strongly associated with insulin resistance, cardiovascular disease, fatty liver disease, and chronic inflammation.

    Potential areas of investigation include:

    • Reduction of visceral adipose tissue

    • Improved body composition

    • Support of lean muscle preservation

    • Improved recovery during calorie restriction

    • Potential improvements in metabolic health

    Although promising, evidence supporting tesamorelin for obesity in otherwise healthy individuals remains substantially smaller than the evidence supporting GLP-based therapies.

    Learn More

Why Different Peptides Exist

Human metabolism is regulated through dozens of overlapping hormonal pathways rather than a single "weight-loss switch."

Different peptides target different aspects of metabolic physiology, including:

  • Appetite regulation

  • Fat storage and fat mobilization

  • Growth hormone secretion

  • Visceral fat metabolism

  • Insulin sensitivity

  • Mitochondrial energy production

  • Muscle preservation

  • Recovery from exercise

  • Inflammation

  • Cellular aging

Because obesity and metabolic disease develop through multiple biological mechanisms, combining therapies that influence different pathways may eventually provide more individualized treatment approaches. However, combination therapy should always be guided by qualified medical professionals and supported by an understanding of each peptide's safety profile.

Emerging Mitochondrial and Metabolic Peptides

The field of peptide medicine continues to evolve rapidly.

Several investigational compounds are being studied for their potential effects on metabolism, including peptides that influence:

  • Brown adipose tissue activation

  • Mitochondrial biogenesis

  • Cellular stress resistance

  • Fat oxidation

  • Insulin signaling

  • Inflammation

  • Muscle metabolism

Many of these compounds remain in early stages of development, and it is likely that the next generation of metabolic therapies will combine multiple complementary mechanisms rather than relying on appetite suppression alone.

Comparing the Current Evidence

Although interest in metabolic peptides continues to grow, the strength of evidence varies considerably between therapies.

Strong clinical evidence

  • Semaglutide

  • Tirzepatide

  • Retatrutide (late-stage clinical trials)

Moderate clinical evidence

  • Tesamorelin (for visceral fat reduction in approved indications)

Early or emerging evidence

  • MOTS-c

  • AOD-9604

  • CJC-1295

  • Ipamorelin

  • Other investigational metabolic peptides

This distinction is important because scientific enthusiasm should always be balanced with the quality of available evidence.

Clinical Perspective

At Arizona Sports Medicine and PROPeptides, we view metabolic peptides as tools—not miracles.

Some therapies possess extensive clinical evidence and well-established safety profiles. Others remain promising areas of ongoing investigation that require considerably more research before their long-term effectiveness can be fully understood.

For many individuals, optimizing sleep, nutrition, resistance training, cardiovascular fitness, stress management, and body composition will produce greater long-term health benefits than relying on any single peptide alone.

As research continues to expand, additional metabolic peptides may eventually become valuable components of personalized treatment plans. Until then, our philosophy remains centered on evidence-based medicine, individualized care, and selecting therapies based on the best available scientific data rather than marketing trends.